Contains Nonbinding Recommendations

Draft Guidance on Zonisamide

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Zonisamide

Form/Route: Capsules/Oral

Recommended studies: 2 studies

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in-vivo
   Strength: 100 mg
   Subjects: Normal healthy males and females, general population. Females must have a negative baseline pregnancy test within 24 hours prior to receiving the drug. Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.
   Additional Comments: Since zonisamide has a long half-life, you can consider performing a parallel design study, truncating the AUC at 72 hours. If you choose to do a crossover design study, the washout period should be adequate to provide for drug elimination. Please verify that zonisamide’s clearance has low intrasubject variability.

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in-vivo
   Strength: 100 mg
   Subjects: Normal healthy males and females, general population. Females must have a negative baseline pregnancy test within 24 hours prior to receiving the drug. Females should not be pregnant or lactating, and if applicable, should practice abstention or contraception during the study.
   Additional Comments: Please see Additional Comments above.

Analytes to measure (in appropriate biological fluid): Zonisamide in serum

Bioequivalence based on (90% CI): Zonisamide

Waiver request of in-vivo testing: 25 mg and 50 mg, based on acceptable (i) bioequivalence studies on the 100 mg capsule, and (ii) proportional similarity of the formulations and (iii) acceptable in vitro dissolution testing of all strengths.

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at http://www.fda.gov/der/ogd/index.htm. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Jan 2008